• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

    6/3/25 7:15:00 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email
    • Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints
    • Denifanstat demonstrated a favorable safety and tolerability profile
    • Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline
    • Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively
    • The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne

    HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264).

    The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics.

    Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001.

    Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported.

    The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition.

    "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis.

    Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively.

    Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (NASDAQ:SGMT) for exclusive rights in Greater China.

    "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne.

    [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055.

    Table 1. Baseline characteristics of Phase III trial of denifanstat

    Baseline characteristics

    50 mg denifanstat, oral, once

    daily

     (n=240)

    Placebo, oral, once daily

     (n=240)

    Total lesion count

    102.2

    102.1

    Inflammatory lesion count

    42.1

    43.1

    IGA=3 (moderate), %

    85.8

    85.8

    IGA=4 (severe), %

    14.2

    14.2

    Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis)

    Efficacy endpoints (1)

    50 mg

    denifanstat, oral,

    once daily

    (n=240)

    Placebo, oral,

    once daily

    (n=240)

    Placebo

    adjusted

    p value

    Percent treatment success (2) (primary

    endpoint)

    33.2

    14.6

    18.6

    <0.0001

    Percent reduction from baseline in total

    lesion count (primary endpoint)

    57.4

    35.4

    22.0

    <0.0001

    Percent reduction from baseline in

    inflammatory lesion count (primary

    endpoint)

    63.5

    43.2

    20.3

    <0.0001

    Percent reduction from baseline in non-

    inflammatory lesion count (key

    secondary endpoint)

    51.9

    28.9

    23.0

    <0.0001

    Absolute reduction from baseline in

    total lesion count (secondary endpoint)

    58.3

    36.2

    22.1

    <0.0001

    Absolute reduction from baseline in

    inflammatory lesion count (secondary

    endpoint)

    26.6

    18.4

    8.2

    <0.0001

    Notes:

    (1)   All efficacy endpoints are least square means.

    (2)   Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12.

    Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison)

    Category

    Denifanstat

     (n=240)

    Sarecycline(1)

    (n=1002)

    Doxycycline(2)

    (n=216)

    Clascoterone

    cream(3)

    (n=722)

    Baseline characteristics

    Total lesion count

    102.2

    72.4

    71.7

    103.6

    Inflammatory lesion count

    42.1

    30.0

    33.6

    42.7

    IGA=3 (moderate), %

    85.8

    85.2

    93.5

    82.7

    IGA=4 (severe), %

    14.2

    14.9

    6.5

    17.3

    Efficacy endpoints at week 12

    Placebo-adjusted percent

    treatment success

    18.6

    9.4

    6.7

    11.6

    Placebo-adjusted percent reduction

    from baseline in total lesion count

    22.0

    NA

    7.6

    11.9

    Placebo-adjusted percent reduction

    from baseline in inflammatory

    lesion count

    20.3

    15.6

    7.3

    12.8

    Placebo-adjusted percent reduction

    from baseline in non-inflammatory

    lesion count

    23.0

    4.5

    NA

    11.4

    Notes:

    (1)   The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA 

    (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf).

    (2)   The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.

    (3)   The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465.

    About Ascletis Pharma Inc.

    Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline.

    For more information, please visit www.ascletis.com.

    Contact: 

    Peter Vozzo

    ICR Healthcare

    443-231-0505 (U.S.)

    [email protected]

    Ascletis Pharma Inc. PR and IR teams

    +86-181-0650-9129 (China)

    [email protected]

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/ascletis-announces-phase-iii-trial-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-meets-all-endpoints-302472286.html

    SOURCE Ascletis Pharma Inc.

    Get the next $SGMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    8/8/2023Outperform
    TD Cowen
    8/8/2023$67.00Overweight
    Piper Sandler
    8/8/2023$33.00Buy
    Goldman
    More analyst ratings

    $SGMT
    Financials

    Live finance-specific insights

    See more
    • Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

      8/14/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

      SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

      6/10/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Martins Eduardo Bruno was granted 34,000 units of Series A Common Stock, increasing direct ownership by 42% to 115,213 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:44:52 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Happel David was granted 116,000 units of Series A Common Stock, increasing direct ownership by 18% to 755,200 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:43:56 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel and CCO Rozek Elizabeth was granted 34,000 units of Series A Common Stock, increasing direct ownership by 21% to 194,506 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:42:54 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

      Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of

      6/4/25 5:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

      Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpointsDenifanstat demonstrated a favorable safety and tolerability profileDenifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycyclineDenifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment

      6/3/25 7:15:00 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025

      SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET. To register, click here. The event will feature Rohit Loomba, MD, MHSc (Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego), who will join company management to discuss the potential for developing a combination of denifanstat, a fat synthesis inhibitor, with a fat ox

      5/22/25 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 7:55:59 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sagimet Biosciences Inc.

      SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 5:05:18 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 4:31:38 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

      SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

      5/6/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SGMT
    SEC Filings

    See more

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      6/4/25 6:03:02 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      5/8/25 6:05:59 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sagimet Biosciences Inc.

      10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)

      5/8/25 6:01:10 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Sagimet Biosciences with a new price target

      Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00

      12/6/24 8:14:45 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Sagimet Biosciences with a new price target

      UBS initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $12.00

      11/12/24 7:50:24 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously

      6/28/24 8:12:54 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      3/28/24 4:08:37 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care